INTRODUCTION Oral morphine has traditionally been considered the WHO ladder step III opioid of first choice for moderate to severe cancer pain (1, 2) . An update of the European Association for Palliative Care (EAPC) recommendations on opioids use in cancer pain (3) showed lack of conclusive studies demonstrating superiority in efficacy and/or tolerability of morphine compared to other oral opioids.
Oxycodone was suggested as one alternative to morphine in the 2001 EAPC recommendations and it recently gained increasing popularity in clinical use (4) (5) (6) . A meta-analysis of five randomized clinical trials (RCTs) (7) , comparing controlled release oral oxycodone (CROO) with controlled release oral morphine (CROM) (8) (9) (10) (11) (12) indicated that pain control did not differ significantly between the two opioids and M A N U S C R I P T
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showed no marked differences in adverse event profile. However, some studies suggested a lower frequency of adverse effects with the use of oxycodone compared to morphine (8, 9, 13) . The variable clearance of potentially toxic morphine metabolites has been considered an explanation for these clinical differences which could be particularly relevant for patients with reduced renal function and in the elderly. Most RCTs comparing oral morphine and oxycodone, were conducted in patients who had already a favorable response to opioid treatment (7, 14, 15) and therefore they could not conclude whether one of the two drugs can be considered superior to the other when used as "first choice opioid" in daily clinical practice. Two open label RCTs comparing the first line administration of CROM and CROO, failed to demonstrate any differences in tolerability or efficacy but none of them specifically defined the clinical outcome in terms of tolerability (11, 12) . Indeed most RCTs comparing different opioids lack methodological quality in the definition, measurement and reporting of AEs as remarked in a recent Cochrane review on opioid adverse effects (16) . Similarly, another systematic review (17) showed a large heterogeneity in the assessment and reporting of AEs among 25 studies on the use of WHO step III opioids for cancer-related pain; as this heterogeneity may influence AEs rates the authors conclude with a urgent need for studies with standardized outcome measures and reporting. On this basis, we carried out a randomized controlled trial aimed at comparing the risk of developing AEs with CROM vs CROO, in patients with cancer pain not exposed to WHO step III opioids in the previous month. Secondary aims were comparing their efficacy on pain intensity reduction, and testing the heterogeneity in the tolerability of the two drugs across different age and renal function patient groups.
MATERIALS AND METHODS Study design
A two arm open-label, parallel-group, multicentre, superiority RCT with a follow-up duration of 14 days was performed in 14 Italian palliative care and oncology units (EudraCT Number: 2006-003151-21; https://www.clinicaltrialsregister.eu/ctrsearch/search?query=2006-003151-21) .
Patient population
Patients with cancer pain were enrolled according to the following inclusion criteria: age = 18 years; previous 24 hours average pain intensity score = 5 on a 0 to 10 numerical rating scale (0-10 NRS); Karnofsky performance status (KPS) score =40; clinical prediction of survival = 1 month; minimum expected follow-up of two weeks at the study centre. Exclusion criteria were: therapy with WHO step III opioids within 30 days of study entry; severe renal impairment; severe hepatic failure; dyspnoea or severe chronic obstructive pulmonary disease; inability to take oral medications; history of psychiatric illness; cerebral metastasis; cognitive impairment; medical history of intolerance to morphine or oxycodone; pregnancy or breast feeding. Administration of hormonotherapy, chemotherapy, analgesic adjuvants (steroids, anticonvulsants and antidepressants) was permitted only if started before study entry, and had to be kept unchanged during the study period. All patients enrolled provided written informed consent. The trial received institutional Ethical Committee approval in all participating institutions before patient enrolment and it was conducted in accordance with the Declaration of Helsinki.
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Randomization
Patients were randomized to either CROM or CROO in a 1:1 ratio via a computergenerated block randomization -block size of 4-; assignment was stratified by age (<70 vs =70 years) and ongoing vs not ongoing chemotherapy (ongoing was defined as administered from 15 days before to 15 days after randomization). Randomization was centralized by a trial office available 8 to 16 all working days and randomization sequence was concealed until interventions assignment.
Treatment
The initial daily dose of the study medication was decided by the treating physician, based on patient characteristics, pain intensity and previous analgesic dosage, according to usual clinical practice. Study medications were taken every 12 hours and the dose was titrated to effect. Dose adjustments during follow-up were encouraged if patients required more than two rescue analgesic doses over 24 hours. Oral immediate release or parenteral morphine, could be prescribed as supplemental analgesics for breakthrough pain. Use of antiemetics and laxatives were permitted for treatment of adverse effects as required.
Study assessments and outcome definition Patient s were assessed at baseline, at 7 and 14 days thereafter. Demographics and clinical data were recorded at baseline; KPS score, and average pain intensity in the previous 24 hrs (0-10 NRS, 0="no pain", 10="The worst possible pain")(18) were collected at each visit. An active surveillance of harms was carried out (18) ; at each visit patients rated the previous week average intensity of a predefined list of potential opioid AEs: nausea, vomiting, confusion, constipation, somnolence, dry mouth, itching and hallucinations (16, 17) . Patients were interviewed by the treating physician using 0-10 NRS (0="No symptom", 10="The worst possible symptom") for all symptoms but hallucinations, which were measured as presence/absence. The study primary outcome was a binary variable indicating AE onset during followup. An AE was considered to occur when there was a worsening of at least 2 points, compared to the baseline, of any side effect listed above, at any of the two follow-up assessments; hallucinations worsening was defined as "presence of any episode during follow-up". Average follow-up pain intensity was the secondary outcome.
Statistical design and analysis
The study was planned as a superiority trial; sample size calculations indicated that 180 patients per group (200 allowing for a 10% drop out rate) would be required to detect a difference between the treatment groups of at least 15% in AE onset with a 95% confidence interval (95%CI) estimate ranging ±11%. The study was prematurely stopped after enrolling 187 patients due to slower than expected accrual rate. No interim analyses were carried out; no post-hoc power calculations were performed and 95%CIs were used when interpreting estimates precision (19, 20) . The ITT population included all randomized patients who received at least one dose of the allocated study drug. Worst case imputation (21) was applied: patients who prematurely discontinued the study for any reason -both before visit on day 7 and day 14-were imputed a "worsening"; complete case and available data analyses (respectively defined as "both" and "at-least-one" non missing follow-up M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT assessments) without any imputation were carried out as sensitivity analyses. For secondary efficacy endpoints, available data analysis with no imputation was applied. In the overall study population the between group risk difference (RD) of developing AEs and its 95%CI were estimated by a logistic regression model; in order to rule out any potential centre-bias, the main outcome analysis was also adjusted by centre. Statistical tests for interaction in multivariable logistic regression models were employed in order to assess heterogeneity of treatment effect across different age (age<70 vs. age=70 years) and renal function (estimated glomerular filtration rate (e-GFR) <60ml/min vs =60 ml/min) groups, as pre-declared in the protocol; e-GFR was calculate from blood creatinine, age, gender and race using the CKD-EPI formula (22) . Tolerability data were also described separately for each single AE, calculating AE occurrence as a worsening = 2 points between baseline and follow-up average score (average of day 7 and day 14). Efficacy in the two treatment groups was compared by ANCOVA summary measure approach as suggested by Frison(23) ; the method consists in averaging pain intensity scores collected at days 7 and 14 for each patient (average follow-up pain intensity score) and using it as dependent variable in an ANCOVA model adjusted by baseline pain intensity; this allowed to estimate the between group "average follow-up pain intensity score" difference which constitute the secondary outcome. Opioid dosages were reported as oral morphine equivalent daily dose (MEDD) mg, converted using a 1.5:1 ratio between CROM and CROO. Between group difference of the opioid escalation index, (i.e. the mean daily percentage increase in opioid dosage) was also reported. Analyses adjusted for age (<70yrs vs. =70 yrs), renal function (e-GFR <60ml/min vs =60 ml/min) , gender and ongoing chemotherapy were also reported for the main tolerability and efficacy outcomes. All statistical analyses were performed using Stata 13 (StataCorp, College Station, TX); raw and adjusted RD were estimated the post-estimation command adjrr (24) . Additional data were provided as online Appendix with tables reporting tolerability and efficacy outcomes by treatment arm, assessment time and covariate subgroups (age and renal impairment).
RESULTS
From Sept14, 2006 to Dec 21, 2007 , 187 eligible patients were randomly allocated either to CROM (95 patients) or CROO (92 patients) as shown in Figure1. Participating centres enrolled a median of 11 patients (range 3-44). Table 1 reports similar background demographic and clinical characteristics for the two groups with the exception of a slightly higher amount of patients with KPS=70 in the CROO group. Study compliance description One patient in each arm did not receive the allocated intervention due to consent withdrawal, and 74 vs. 72 patients, 78% in both groups, completed the study ( Figure  1 ). All hospitalizations and deaths (seven patients) were due to disease progression; protocol violations were due to cognitive impairment (two patients) and inability to take oral medications (two patients); one patient failed to fill-in baseline main outcome evaluation. Nine patients (three and six respectively with CROM and CROO) discontinued treatment due to AEs ( Table 2 ); in four patients (two in both groups) the AEs were deemed "not related" with the study drug and in five cases (one with CROM and four with CROO) the relationship with the study drug was classified as "certain or probable". The two patients who did not receive the allocated intervention were excluded from the ITT analysis on the main outcome ( Figure 1 ).
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Primary tolerability endpoint in the overall sample, by age and renal function. The percentages of patients reporting an AE during treatment were 84.0% and 84.6% in the CROM and in the CROO groups respectively, unadjusted RD -0.6% (95%CI from -11.0% to 9.9%) ( Figure 2 , overall sample). Risk difference adjusted by centre of was not substantially different from the unadjusted estimate (RD -1.0%, 95%CI from -11.8% to 9.8% -data not reported in figure) . Also sensitivity analyses for missing data imputation assumption in unadjusted analysis provided similar results: a RD of -0.6% (95%CI from -13.5% to 12.3%) with complete case analysis (N=74 and N=72 in CROM and CROO groups) and a RD of -1.5% (95%CI from -13.8% to 10.7%) with available data analysis (N=88 and N=85). When examining the two models respectively adjusted by age (<70yrs vs. =70 yrs), and by renal function (e-GFR <60ml/min vs =60 ml/min), no evidence of heterogeneity of treatment effect across subgroups was found: none of the two interaction parameters (treatment by age and treatment by renal function) resulted significant (p=0.11 for age and p=0.63 for renal function) and, consistently, 95%CIs of adjusted RDs both contained zero (Figure 2 , renal impairment and age). RD was -6.8% (95%CI -21.2% to 7.5%) vs 15% (95%CI -3.3% to 33%) respectively in younger and older patients ( Figure 2 ) and -6.2% (95%CI -18.5% to 5.9%) vs 1% (95%CI -24% to 26%) in patients with normal and moderately impaired renal function. A final model adjusting for age, renal function, gender and ongoing chemotherapy on ITT population, provided slightly higher still non-significant adjusted RD (-4.6% , 95%CI from -15.3% to 6.2% -data not reported in figure) . Due to missing in covariates, sample size for this last analysis is 83 and 84 respectively in CROM and CROO group.
Detailed adverse effect profile Separate results for each AE are shown in Figure 3 . Some symptoms were already present at baseline with no marked differences between the two arms ( Figure 3-A) . Figure 3 -B shows the percentages of patients reporting baseline to follow-up worsening of at least two points by treatment group: worsening of nausea (15% vs. 21%, RD 95%CI -17% to 5%), constipation (25% vs. 35%, 95%CI -23% to 4%) and dry mouth (16% vs. 22%, RD 95%CI -18% to 5%) were numerically more frequent with CROO, whereas somnolence (35% vs. 32%, 95%CI RD -10% to 17%) with CROM. No patients experienced hallucination at baseline. Seven patients (four in CROM and three in CROO groups) had visual hallucinations which resolved spontaneously and did not require to stop treatment except in one patient (data not reported in Figure) . In both groups, about two thirds of patients were prescribed laxatives, while antiemetics were used less frequently (around 40%) ( Figure 4 ).
Pain relief and opioid dosage
Average follow-up pain intensity score was 3.3 vs. 3.5 on a 0-10 NRS respectively for CROM and CROO, with a between group difference of -0.3 (95%CI -0.8 to 0.3) after adjusting for baseline pain intensity (Table 3 ). When adjusting also for age, renal function, gender and ongoing chemotherapy, as well as for baseline pain intensity, follow-up pain intensity difference between the two drugs was substantially the same as the one estimated unadjusted analysis (-0.4 and 95%CI -1.0 to 0.2, data not reported in table); due to missing in covariates, sample size for this last analysis is 77 and 78 respectively in CROM and CROO groups. Average MEDD prescribed at M A N U S C R I P T
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baseline were comparable between CROM and CROO (30.9 mg and 36.6 mg respectively); end of study average MEDD, including around the clock and as needed dosages, (53.9 mg for CROM and 69.8 mg for CROO) point to similar opioid dose escalation for the two drugs, with a between group difference of -1.8% (95%CI -5.4% to 1.7%) ( Table 3 ).
DISCUSSION
The results of this open label multicenter RCT fail to show any difference in the risk of developing AEs and in analgesic effect between CROM to CROO when the used as first line WHO step III opioid for cancer pain. To our knowledge this is the first study addressing tolerability as primary outcome in comparing CROO and CROM as first line opioid for cancer pain and also the first using an active surveillance of harms (7, 16) . Heiskanen and Kalso (8) showed similar frequencies of AEs with the two drugs, although vomiting was more frequent (p<0.01) with morphine, and constipation more common with oxycodone (p<0.01). Mucci-LoRusso et al. (9) reported side effects in 83% for oxycodone and 75% for morphine with a statistically significant lower incidence regarding itching with oxycodone (p<0.04) and 2 cases of hallucinations with morphine. No significant differences in adverse effects were reported by other authors (8) (9) (10) (11) (12) .
Our study also shows that some symptoms were already present at baseline ( Figure 3 -A); the concurrent effect of antineoplastic therapies can cause side effects per se, by modifying the kinetics of opioids and/or adjuvant antiemetic medications; advanced disease and comorbidities may also concur to the etiology of several symptoms such as nausea or vomiting.. This confirms the importance of an active surveillance of harms and closely reflects clinical practice when adverse effects can have a multifactor aetiology (16) . The rate of AE worsening, around 85% in both groups, confirms previous data (25) and may have different explanations: active surveillance of potential AEs, low cut off used for the definition of AE (i.e. any symptom worsening =2 on any of the two follow-up assessments) and a broad definition of the tolerability outcome which did not consider the relationship of the symptom to the analgesic treatment. Yet, only 5 patients dropped out because of AEs judged as potentially related to the study drug. The use of opioids in patients with reduced renal function has recently been appraised in a systematic review(26) showing evidence of morphine metabolytes accumulation. Case series and pharmacodynamic models based on humane experimental data support possibility of an enhanced efficacy at lower morphine doses and increased risk of side effects(26, 27). At the same time the clinical impact of renal impairment in affecting different opioids toxicity is poorly documented(26).Also oxycodone has active metabolytes but their clinical effect and the eventual impact of renal impairment are even less documented(26, 28) The effect of age on opiods pharmacodynamics is also known(29). Elderly have been shown to be sensitive to relatively lower doses of morphine probably due to a combiniation of dynamics and kinetics factors(30).In our study, AEs were numerically more frequent with CROM than with CROO among elderly patients while no relevant differences emerged for patients with moderate renal impairment ( Figure 2) ; also due to the reduced number of patients in the stratified groups, RD estimates by subgroup were imprecise ( Figure  2) , which advocates for further investigation of this debated issue. This study has some limitations. It was stopped early because of slow recruitment rate but, since the reason for stopping was independent of trial findings, it is unlikely that bias was introduced in the study results (19) . Conversely, a decrease in the estimates M A N U S C R I P T
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precision occurred because of the sample size reduction; nonetheless the sample size reached in our study is the second largest in RCTs comparing CROM to CROO (7) . Patient attrition, 22% in both groups, was another potential limitation but it was lower than what commonly found in studies performed in palliative care(31) and worst case imputation, applied according to EMA indication for responder analyses reporting on AEs (21) , allowed to carry out ITT analysis on 99% of enrolled patients. A further potential limitation of the study is given by the choice of an unidimensional main outcome summarizing effect on multiple symptoms. Although this may have had an impact on assay sensitivity of the trial, secondary tolerability analyses confirmed no statistically nor clinically meaningful differences on any of the AEs when analysed separately. Finally, the open-label design may have resulted in a biased estimate of the study endpoints; it is possible that knowledge of the treatment received has systematically altered patient-reported outcomes because of likely differences in the way morphine and oxycodone are perceived: morphine may be more known than oxycodone and more often associated with the negative attitudes surrounding the use of strong opioids. However this mirrors daily clinical practice in which patients do actually know the opioid they take. The choice of the open label design was also aimed at avoiding that complexity of the blinding procedures could interfere with normal practice and decreased the number of patients enrolled. Rigorous clinical trials are an essential step in the development of evidence based palliative care, but difficulties in running clinical studies in this setting are well known and only partially overcome(32, 33).Although we designed our study to reflect clinical practice as much as possible we did not reach the desired sample size mainly because a number of potential participating centers actually did not take part into the study and because some smaller ones enrolled only a limited number of patients. This seems common in other recently published RCT(34, 35) and indeed several consideration may apply in designing studies with shorter follow up periods and in enhancing the skills in screening the population of interest; however difficulties are also related to patient who are lost to follow up for reasons unrelated to the study conditions(31) and to the gate-keeping attitude of some health care providers who are often reluctant to refer advanced patients for research protocols(36). Although our results and results from previous studies, were inconclusive in showing superiority of any of the two drugs over the other, the evidence now available justifies the hypothesis of equivalence between morphine and oxycodone for moderate to severe pain to be tested in future studies. Nonetheless, in the hypothesis of 85% AE occurrence as in the present study, properly designed equivalence studies (alpha level 0.05, power 0.8 ) aimed at estimating between arm AE risk difference within an equivalence limit of 5% would require sample sizes of 2146 patients(37). While this is not to be considered a post hoc power calculation, it adds values to the publication of inconclusive results to encourage subsequent execution of data meta-analyses.
CONCLUSION
Our study does not bring conclusive results on the relative tolerability and efficacy of CROM and CROO mainly due to the insufficient sample size reached, to the potential bias introduced by the open-label design and to the difficulty in evaluating assay sensitivity of the trial. Also the hypothesis of a lower risk of toxicity with oxycodone among elderly patients and among those with moderate renal impairment warrants further investigations. These data, however, can significantly contribute to future meta-analyses comparing WHO-stepIII opioids and is relevant in designing future M A N U S C R I P T
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